Drugs / Octaplex
Trials 6 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 34 trials | ||||||
| Phase 3 | NCT05523297 | Nov 2022 → Jun 2024 | — | Octapharma | Completed | No outcome recorded |
| Phase 3 | NCT04867837 | Sep 2021 → Jan 2026 | — | Octapharma | Terminated | No outcome recorded |
| Phase 3 | NCT02740335 | Jun 2017 → Feb 2022 | — | Octapharma | Completed | No outcome recorded |
| Phase 3 | NCT00618098 | May 2008 → Mar 2012 | — | Octapharma | Completed | No outcome recorded |
| Phase 42 trials | ||||||
| Phase 4 | NCT04534751 | Apr 2021 → Dec 2023 | blood coagulation disease | University Health Network, Toronto | Unknown | No outcome recorded |
| Phase 4 | NCT01910675 | Jul 2013 → Oct 2018 | — | Helsinki University Central Hospital | Withdrawn | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 7 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Octaplex | “Intervention group: 4 g Fibryga and 2000 IU Octaplex will be released as part of the first and second MHP packs.” NCT04534751 ↗ |
| Known as | Balfaxar | “The primary objective is to determine whether 4F-PCC (Octaplex/Balfaxar, Octapharma) is clinically non-inferior to FP for haemostatic effectiveness.” PMID 39174056 ↗ Aug 2024 |
| Modality | Protein / enzyme biologic | “Octaplex (human prothrombin complex concentrate)” NCT00618098 ↗ |
| Route | Intravenous | “Octaplex infusions intravenously” NCT00618098 ↗ |